Journal of Thrombosis and Thrombolysis

, Volume 33, Issue 3, pp 287–295 | Cite as

Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia

  • James W. Wisler
  • Jeffrey B. Washam
  • Richard C. BeckerEmail author


Bivalirudin, a direct thrombin inhibitor, is indicated for patients with suspected heparin-induced thrombocytopenia (HIT) with anticipated percutaneous coronary intervention (PCI). Data is limited on dose selection among patients with renal insufficiency, particularly with prolonged infusion durations. The study cohort comprised 73 patients with renal dysfunction who received bivalirudin for suspected HIT with or without acute coronary syndrome. We reviewed individual pharmacy and medical records for laboratory and bivalirudin dosing information, medical comorbidities, and adverse clinical outcomes during administration. When estimated glomerular filtration rate (eGFR) was calculated by the Cockcroft–Gault (CG; ml/min) formula, the average bivalirudin dose (mg/kg/h) achieving a therapeutic activated partial thromboplastin time (aPTT) was 0.07 ± 0.04, 0.15 ± 0.08, and 0.16 ± 0.07 for patients with eGFR between 15–30, 31–60, and >60, respectively. When eGFR was calculated by the modification of diet in renal disease (MDRD; ml/min/1.73 m2) formula, the average bivalirudin dose achieving a therapeutic aPTT was 0.07 ± 0.04, 0.12 ± 0.07, and 0.20 ± 0.07 for patients with eGFR between 15–30, 31–60, >60, respectively. The difference between the dose achieving a therapeutic aPTT for patients with eGFR >60 when calculated by MDRD versus CG was completely abolished when obese patients were excluded from the CG cohort. The results of our series of patients with renal dysfunction receiving prolonged duration of bivalirudin in the setting of acute coronary syndrome (ACS) suggests that dose adjustment is safe and should be considered for patients with moderate to severe renal impairment (eGFR < 60 ml/min/1.73 m2).


Bivalirudin Renal insufficiency Heparin-induced thrombocytopenia 



We would like to acknowledge the contributions of Dr. Christopher Meduri and Dr. Christopher Huff for their assistance with data collection and obtaining IRB approval.


  1. 1.
    Bartholomew J (2004) Bivalirudin for the treatment of heparin induced thrombocytopenia. In: Warkentin T, Greinacher A (eds) Heparin-induced thrombocytopenia, 3rd edn. Marcel Dekkar, New YorkGoogle Scholar
  2. 2.
    Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin E, Hanson D, Mant T, Wagner J, Maraganore J (1993) Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 69(2):157–163PubMedGoogle Scholar
  3. 3.
    Robson R, White H, Aylward P, Frampton C (2002) Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther 71(6):433–439. doi: 10.1067/mcp.2002.124522 PubMedCrossRefGoogle Scholar
  4. 4.
    Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ (2003) Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289(7):853–863PubMedCrossRefGoogle Scholar
  5. 5.
    Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355(21):2203–2216PubMedCrossRefGoogle Scholar
  6. 6.
    Chew DP, Lincoff AM, Gurm H, Wolski K, Cohen DJ, Henry T, Feit F, Topol EJ (2005) Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol 95(5):581–585. doi: 10.1016/j.amjcard.2004.11.003 PubMedCrossRefGoogle Scholar
  7. 7.
    Warkentin TE, Greinacher A (2004) Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl):311S–337S. doi: 10.1378/chest.126.3_suppl.311S PubMedCrossRefGoogle Scholar
  8. 8.
    Angiomax [package insert] (2002) The Medicines Company, ParsippanyGoogle Scholar
  9. 9.
    Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31–41PubMedCrossRefGoogle Scholar
  10. 10.
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6):461–470PubMedGoogle Scholar
  11. 11.
    Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694. doi: 10.1111/j.1538-7836.2005.01204.x PubMedCrossRefGoogle Scholar
  12. 12.
    Kiser TH, Burch JC, Klem PM, Hassell KL (2008) Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. Pharmacotherapy 28(9):1115–1124. doi: 10.1592/phco.28.9.1115 PubMedCrossRefGoogle Scholar
  13. 13.
    Kiser TH, Fish DN (2006) Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy 26(4):452–460. doi: 10.1592/phco.26.4.452 PubMedCrossRefGoogle Scholar
  14. 14.
    Runyan CL, Cabral KP, Riker RR, Redding D, May T, Seder DB, Savic M, Hedlund J, Abramson S, Fraser GL (2011) Correlation of bivalirudin dose with creatinine clearance during treatment of heparin-induced thrombocytopenia. Pharmacotherapy 31(9):850–856. doi: 10.1592/phco.31.9.850 PubMedCrossRefGoogle Scholar
  15. 15.
    Robson R (2000) The use of bivalirudin in patients with renal impairment. J Invasive Cardiol 12 Suppl:F33–F36Google Scholar
  16. 16.
    Demirovic JA, Pai AB, Pai MP (2009) Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 66(7):642–648. doi: 10.2146/ajhp080200 PubMedCrossRefGoogle Scholar
  17. 17.
    Spruill WJ, Wade WE, Cobb HH 3rd (2007) Estimating glomerular filtration rate with a modification of diet in renal disease equation: implications for pharmacy. Am J Health Syst Pharm 64(6):652–660. doi: 10.2146/ajhp060239 PubMedCrossRefGoogle Scholar
  18. 18.
    Michaels AD, Spinler SA, Leeper B, Ohman EM, Alexander KP, Newby LK, Ay H, Gibler WB (2010) Medication errors in acute cardiovascular and stroke patients: a scientific statement from the American Heart Association. Circulation 121(14):1664–1682. doi: 10.1161/CIR.0b013e3181d4b43e PubMedCrossRefGoogle Scholar
  19. 19.
    Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG (2003) Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 163(15):1849–1856. doi: 10.1001/archinte.163.15.1849 PubMedCrossRefGoogle Scholar
  20. 20.
    Lubenow N, Eichler P, Lietz T, Farner B, Greinacher A (2004) Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 104(10):3072–3077. doi: 10.1182/blood-2004-02-0621 PubMedCrossRefGoogle Scholar
  21. 21.
    Dang CH, Durkalski VL, Nappi JM (2006) Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy 26(4):461–468. doi: 10.1592/phco.26.4.461 PubMedCrossRefGoogle Scholar
  22. 22.
    Lincoff AM, Bittl JA, Kleiman NS, Sarembock IJ, Jackman JD, Mehta S, Tannenbaum MA, Niederman AL, Bachinsky WB, Tift-Mann J 3rd, Parker HG, Kereiakes DJ, Harrington RA, Feit F, Maierson ES, Chew DP, Topol EJ (2004) Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 93(9):1092–1096. doi: 10.1016/j.amjcard.2004.01.033 PubMedCrossRefGoogle Scholar
  23. 23.
    Poggio ED, Nef PC, Wang X, Greene T, Van Lente F, Dennis VW, Hall PM (2005) Performance of the Cockcroft–Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. Am J Kidney Dis 46(2):242–252. doi: 10.1053/j.ajkd.2005.04.023 PubMedCrossRefGoogle Scholar
  24. 24.
    K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification (2002) Am J Kidney Dis 39(2 Suppl 1):S1–266Google Scholar
  25. 25.
    den Hartog JR, Reese PP, Cizman B, Feldman HI (2009) The costs and benefits of automatic estimated glomerular filtration rate reporting. Clin J Am Soc Nephrol 4(2):419–427CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • James W. Wisler
    • 1
  • Jeffrey B. Washam
    • 2
  • Richard C. Becker
    • 1
    • 3
    Email author
  1. 1.Division of CardiologyDuke UniversityDurhamUSA
  2. 2.Duke Heart CenterDuke UniversityDurhamUSA
  3. 3.Duke Clinical Research InstituteDuke UniversityDurhamUSA

Personalised recommendations